Phase I and clinical pharmacological evaluation of aphidicolin glycinate

Cristiana Sessa, Massimo Zucchetti, Enrico Davoli, Raffaele Califano, Franco Cavalli, Sergio Frustaci, Lindsey Gumbrell, Aaron Sulkes, Benjamin Winograd, Maurizio D'incalci

Research output: Contribution to journalArticlepeer-review

Abstract

The toxicity profile and the pharmacominetics of ashidicolin glycinate, a water-soluble; ilogue of aphidicolin, have been evaluated in two consecutive phase I clinical studies. In the first study, aphidicolin glycinate was given by 1-hour infusion on for 5 consecutive days, every 3 weeks (daily x 5 study); in the second study, which was planned on the basis of the pharmacokinetic information obtained in the previous study, the drug was given by 24-hour continuous infusion. Treatment was repeated every 3 weeks. In the daily x 5 study, the daily dose was escalated from 12 mg/m2 to the maximum tolerated dose of 2250 mg/m2. Local toxicity was dose limiting. Elimination half-life was 2 ± 0.2 hours (mean ± SE), with aphidicolin being undetectable 6-8 hours after the end of the infusion. In the 24-hour continuous-infusion study, the dose was escalated from 435 mg/m2 to the maximum tolerated dose of 4500 mg/m2. Local toxicity was dose limiting, while other toxic effects were absent. The experimentally determined concentrations at the steady state were in agreement with those predicted on the basis of the available pharmacokinetic data. The targeted concentration at the steady state of 3 μg/mL was achieved at doses greater than or equal to 3000 mg/m2. Twenty-four-hour continuous infusion is the recommended schedule for clinical evaluations of aphidicolin glycinate as the synchronizing agent or in combination with cisplatin. [J Natl Cancer Inst 83: 1160-1164,1991]

Original languageEnglish
Pages (from-to)1160-1164
Number of pages5
JournalJournal of the National Cancer Institute
Volume83
Issue number16
DOIs
StatePublished - 21 Aug 1991
Externally publishedYes

Fingerprint

Dive into the research topics of 'Phase I and clinical pharmacological evaluation of aphidicolin glycinate'. Together they form a unique fingerprint.

Cite this